Two-pronged therapeutic approach for glioblastoma: high dose radiation therapy then repair of radiation-induced brain injury
胶质母细胞瘤的双管齐下治疗方法:高剂量放射治疗然后修复放射引起的脑损伤
基本信息
- 批准号:9751998
- 负责人:
- 金额:$ 15.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2019-11-10
- 项目状态:已结题
- 来源:
- 关键词:AchievementAcuteAstrocytesBlood VesselsBrainBrain InjuriesBrain NeoplasmsCalciumCellsCellular StructuresCerebrovascular systemComplexDataDependenceDevelopmentDiseaseDoseEndotheliumEngraftmentFunctional ImagingGlioblastomaGliomaHemorrhageImageImmunocompetentIndividualInjuryIntra-Arterial InjectionsIschemiaLabelLiteratureMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of brainMaximum Tolerated DoseMitoticModelingMolecularMolecular BiologyMusNervous System PhysiologyNeurogliaNeurological ModelsNeuronsPatientsPeripheralPrimary Brain NeoplasmsRadiationRadiation Dose UnitRadiation InjuriesRadiation induced damageRadiation therapyRegenerative MedicineReporterResearchResistanceRodentRodent ModelSignal TransductionSiteTestingTherapeuticTherapeutic InterventionTimeTissuesTransgenic AnimalsTransgenic OrganismsTransplantationWorkXenograft procedureanatomic imagingbasebioluminescence imagingdysmyelinationexperimental studyfetalimaging platformimprovedintravital imagingmultimodalitymyelinationnervous system disorderneuro-oncologyneurorestorationoncologypreservationpreventprogenitorradiation effectrecruitregenerativerepairedrestorative treatmenttooltreatment responsetreatment strategytumortwo photon microscopywhite matterwhite matter damage
项目摘要
Over the last few decades, we have witnessed exceptional progress in the fields of regenerative medicine and
oncology in terms of defining molecular mechanisms of disease, developing research tools (molecular biology,
imaging, transgenic animals) and identifying treatment strategies. While these two fields have overall divergent
targets they are can be envisioned as being complementary. Further interfacing is needed: in particular, the
field of neuro-oncology may greatly benefit from exploiting all the recent achievements in regenerative
medicine. Glioblastoma multiforme (GBM) accounts for approximately 65% of all primary brain tumors and is
characterized by low survival, with only 10% of patients surviving >5 years. Radiation therapy dose escalation
has been explored but now abandoned due to radiation-induced brain injury, which is primarily manifested by
damage to white matter and cerebral vasculature. We believe we can make significant advancements in
developing a better cure for GBM. Our preliminary experiments indicate that tumors can be completely
eradicated with radiation therapy provided that the dose is sufficiently high. We have shown complete
elimination of tumors without reoccurrence with a single dose of 40 or 80 Gy. Importantly, the injury as
manifested by white matter damage and the occurrence of hemorrhage as seen on magnetic resonance
imaging (MRI) was detectable after 2-3 months, providing an ample time window for therapeutic intervention.
We propose to perform a detailed characterization of radiation-induced brain injury following high dose
radiation therapy and to test the feasibility of regenerative approaches aiming at reversing or preventing the
injury to the most vulnerable components (white matter and vasculature). To this end, we will use a state-of-the
art multimodal intravital imaging platform with MRI, bioluminescence imaging (BLI) and two-photon microscopy
(2PM).
在过去的几十年里,我们见证了再生医学和
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Unlocking the potential of ultra-high dose fractionated radiation for effective treatment of glioblastoma.
释放超高剂量分割放射有效治疗胶质母细胞瘤的潜力。
- DOI:10.21203/rs.3.rs-3500563/v1
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Lan,Xiao-Yan;Kalkowski,Lukasz;Chu,Cheng-Yan;Jablonska,Anna;Li,Shen;Kai,Mihoko;Gao,Yue;Janowski,Miroslaw;Walczak,Piotr
- 通讯作者:Walczak,Piotr
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Piotr Walczak其他文献
Piotr Walczak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Piotr Walczak', 18)}}的其他基金
Treatment of ALS based on transplantation of glial restricted progenitors
基于神经胶质限制性祖细胞移植的 ALS 治疗
- 批准号:
9295061 - 财政年份:2015
- 资助金额:
$ 15.33万 - 项目类别:
Efficient Targeting of Therapeutic Cells in Stroke and EAE
中风和 EAE 治疗细胞的有效靶向
- 批准号:
8370236 - 财政年份:2012
- 资助金额:
$ 15.33万 - 项目类别:
Efficient Targeting of Therapeutic Cells in Stroke and EAE
中风和 EAE 治疗细胞的有效靶向
- 批准号:
8473291 - 财政年份:2012
- 资助金额:
$ 15.33万 - 项目类别:
Efficient Targeting of Therapeutic Cells in Stroke and EAE
中风和 EAE 治疗细胞的有效靶向
- 批准号:
8848148 - 财政年份:2012
- 资助金额:
$ 15.33万 - 项目类别:
Efficient Targeting of Therapeutic Cells in Stroke and EAE
中风和 EAE 治疗细胞的有效靶向
- 批准号:
8654367 - 财政年份:2012
- 资助金额:
$ 15.33万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 15.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 15.33万 - 项目类别:
Operating Grants














{{item.name}}会员




